Suppr超能文献

骨质疏松症:当前概念

Osteoporosis: Current Concepts.

作者信息

Akkawi Ibrahim, Zmerly Hassan

机构信息

Orthopaedics and Traumatology Unit, Villa Erbosa Hospital, Bologna, Italy.

出版信息

Joints. 2018 Jun 14;6(2):122-127. doi: 10.1055/s-0038-1660790. eCollection 2018 Jun.

Abstract

Osteoporosis is a worldwide disease characterized by reduction of bone mass and alteration of bone architecture resulting in increased bone fragility and increased fracture risk. Causes of osteoporosis include increasing age, female sex, postmenopausal status, hypogonadism or premature ovarian failure, low body mass index, ethnic background, rheumatoid arthritis, low bone mineral density (BMD), vitamin D deficiency, low calcium intake, hyperkyphosis, current smoking, alcohol abuse, immobilization, and long-term use of certain medications. The diagnosis of osteoporosis is established by measurement of BMD of the hip and spine using dual energy X-ray absorptiometry. According to the World Health Organization criteria, osteoporosis is defined as a BMD that lies 2.5 standard deviation or more below the average value for young healthy women. Bone turnover biomarker detection may be useful in monitoring osteoporosis treatment and assessing fracture risk but not for diagnosis of osteoporosis. Management of osteoporosis consists of nonpharmacological interventions, which are recommended for all subjects, and pharmacological therapy in all postmenopausal women who have had an osteoporotic fracture or have BMD values consistent with osteoporosis.

摘要

骨质疏松症是一种全球性疾病,其特征是骨量减少和骨结构改变,导致骨脆性增加和骨折风险升高。骨质疏松症的病因包括年龄增长、女性性别、绝经后状态、性腺功能减退或卵巢早衰、低体重指数、种族背景、类风湿性关节炎、低骨矿物质密度(BMD)、维生素D缺乏、钙摄入不足、脊柱后凸、当前吸烟、酗酒、制动以及长期使用某些药物。骨质疏松症的诊断通过使用双能X线吸收法测量髋部和脊柱的BMD来确定。根据世界卫生组织的标准,骨质疏松症被定义为BMD比年轻健康女性的平均值低2.5个标准差或更多。骨转换生物标志物检测在监测骨质疏松症治疗和评估骨折风险方面可能有用,但不能用于骨质疏松症的诊断。骨质疏松症的管理包括非药物干预措施(推荐给所有患者)以及对所有发生过骨质疏松性骨折或BMD值符合骨质疏松症的绝经后女性进行药物治疗。

相似文献

1
Osteoporosis: Current Concepts.
Joints. 2018 Jun 14;6(2):122-127. doi: 10.1055/s-0038-1660790. eCollection 2018 Jun.
3
Anti-resorptive therapy for the prevention of postmenopausal osteoporosis : when should treatment begin?
Treat Endocrinol. 2005;4(5):263-77. doi: 10.2165/00024677-200504050-00001.
6
[Prevalence of osteoporosis in male patients with risk factors].
Presse Med. 2011 Nov;40(11):e489-98. doi: 10.1016/j.lpm.2011.08.002. Epub 2011 Oct 2.
9
Prevalence of low bone mass in postmenopausal Kuwaiti women residents in the largest province of Kuwait.
Arch Osteoporos. 2012;7:147-53. doi: 10.1007/s11657-012-0092-1. Epub 2012 Sep 1.

引用本文的文献

1
The Protective Activity of Apigenin Against Bone and Cartilage Diseases.
Clin Interv Aging. 2025 Aug 13;20:1235-1251. doi: 10.2147/CIA.S529148. eCollection 2025.
3
4
Recent Advances on the Analysis and Biological Functions of Cinnamaldehyde and Its Derivatives.
Antioxidants (Basel). 2025 Jun 22;14(7):765. doi: 10.3390/antiox14070765.
5
Menopausal Status-Dependent Alterations in Bone Mineral Density in Women Transitioning from Menopause to Postmenopause: An Observational Multicenter Study.
Sage Open Aging. 2025 Jun 24;11:30495334251345095. doi: 10.1177/30495334251345095. eCollection 2025 Jan-Dec.
8
Osteoporosis screening practice at the National Guard affiliated primary care centers, Riyadh, Saudi Arabia.
Saudi Med J. 2025 Jun;46(6):649-658. doi: 10.15537/smj.2025.46.6.20240944.
10
Engineered -Derived Outer Membrane Vesicles Targeting Bone Microenvironment to Improve Osteoporosis.
Biomedicines. 2025 Apr 2;13(4):847. doi: 10.3390/biomedicines13040847.

本文引用的文献

2
Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: A systematic review and meta-analysis.
Semin Arthritis Rheum. 2018 Aug;48(1):44-52. doi: 10.1016/j.semarthrit.2017.12.001. Epub 2017 Dec 7.
4
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.
Bone. 2017 Dec;105:11-17. doi: 10.1016/j.bone.2017.08.003. Epub 2017 Aug 5.
5
New anabolic therapies for osteoporosis.
Intern Emerg Med. 2017 Oct;12(7):915-921. doi: 10.1007/s11739-017-1719-4. Epub 2017 Aug 5.
6
Osteoporosis.
Ann Intern Med. 2017 Aug 1;167(3):ITC17-ITC32. doi: 10.7326/AITC201708010.
7
Bone Mineral Density Response from Teriparatide in Patients with Osteoporosis.
HSS J. 2017 Jul;13(2):171-177. doi: 10.1007/s11420-016-9537-1. Epub 2017 Feb 1.
8
Economic Consequences and Potentially Preventable Costs Related to Osteoporosis in the Netherlands.
Value Health. 2017 Jun;20(6):762-768. doi: 10.1016/j.jval.2017.02.006. Epub 2017 Mar 27.
9
Strontium and strontium ranelate: Historical review of some of their functions.
Mater Sci Eng C Mater Biol Appl. 2017 Sep 1;78:1222-1230. doi: 10.1016/j.msec.2017.05.042. Epub 2017 May 9.
10
Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives.
Biomark Res. 2017 May 18;5:18. doi: 10.1186/s40364-017-0097-4. eCollection 2017.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验